Moderna Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:3em;'>MRN</div>
MRNA -- USA Stock  

USD 124.73  4.92  3.79%

Why analysts lower the entity buy or sell consensus to Hold? The next fiscal quarter end is expected on the 31st of December 2020. As many millenniums are getting excited about healthcare space, it is only fair to go over the feasibility of shorting Moderna. We will evaluate why we are still optimistic in anticipation of a recovery. Analysts now have less confidence in Moderna as compared to a month ago. The current buy or sell recommendation of 14 analysts is Hold.
Published over two weeks ago
View all stories for Moderna | View All Stories
What is January outlook for Moderna (NASDAQ:MRNA)?
On a scale of 0 to 100, Moderna holds a performance score of 11. The company secures a Beta (Market Risk) of -0.2563, which conveys not very significant fluctuations relative to the market. Let's try to break down what Moderna's beta means in this case. As returns on the market increase, returns on owning Moderna are expected to decrease at a much lower rate. During the bear market, Moderna is likely to outperform the market. Although it is vital to follow Moderna price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-seven technical indicators for Moderna, which you can use to evaluate the performance of the firm. Please exercises Moderna coefficient of variation, maximum drawdown, skewness, as well as the relationship between the total risk alpha and downside variance to make a quick decision on whether Moderna current price movements will revert.
What is the right price you would pay to acquire a share of Moderna? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Moderna this year

Annual and quarterly reports issued by Moderna are formal financial statements that are published yearly and quarterly and sent to Moderna stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Moderna often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Moderna utilizes its cash?

To perform a cash flow analysis of Moderna, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Moderna is receiving and how much cash it distributes out in a given period. The Moderna cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Moderna Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (413.07 Million)

Moderna exotic insider transaction detected

Legal trades by Moderna insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Moderna insider trading alert for general transaction of common stock by Bancel Stephane, Chief Executive Officer, on 15th of January 2021. This event was filed by Moderna Inc with SEC on 2021-01-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Average experts consensus on the stock has changed. Currently, most analysts have less confidence in Moderna as compared to a month ago. The current buy or sell recommendation of 14 analysts is Hold. Earning per share calculations of Moderna is based on official Zacks consensus of 6 analysts regarding Moderna's future annual earnings. Given the historical accuracy of 83.78%, the future earnings per share of the company is estimated to be -1.6422 with the lowest and highest values of -2.13 and -1.05, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.

Is Moderna a risky opportunity?

Let's check the volatility. Moderna is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Moderna (NASDAQ:MRNA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Moderna stock makes you a part-owner of that company.

Moderna Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Moderna. The Moderna consensus assessment is calculated by taking the average estimates from all of the analysts covering Moderna

Strong Buy
Strong Sell
Strong Buy642.86
Strong Sell17.14

Moderna bad events are not so bad

Risk adjusted performance is down to 0.21. It may suggest a possible volatility slip. Moderna shows above-average downside volatility for the selected time horizon. We advise investors to inspect Moderna further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Moderna future alpha.

Our Takeaway on Moderna Investment

Whereas some firms in the biotechnology industry are either recovering or due for a correction, Moderna may not be performing as strong as the other in terms of long-term growth potentials. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to quit some or all of your Moderna holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Moderna.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Moderna. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to